Apaziquone
- Generic Name
- Apaziquone
- Drug Type
- Small Molecule
- Chemical Formula
- C15H16N2O4
- CAS Number
- 114560-48-4
- Unique Ingredient Identifier
- H464ZO600O
- Background
Apaziquone has been investigated for the treatment of Bladder Cancer and Bladder Neoplasms.
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT02563561
- Locations
- 🇺🇸
The Urology Center of Colorado, Denver, Colorado, United States
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 47
- Registration Number
- NCT01469221
- Locations
- 🇵🇱
Centrum Medycznego Kształcenia Podyplomowego, Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego, Warszawa, Poland
🇵🇱Niepubliczny Zakład Opieki Zdrowotnej-Centrum Medyczne Szpital Świętej Rodziny sp z o.o., Łódź, Poland
🇸🇰Univerzitná nemocnica L. Pasteura Košice Univerzitná nemocnica L. Pasteura Košice, Košice, Slovakia
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 66
- Registration Number
- NCT01410565
- Locations
- 🇨🇦
G. Steinhoff Clinical Research Pacific Urologic Research, Victoria, British Columbia, Canada
🇨🇦Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
🇺🇸Idaho Urologic Institute, P.A., Meridian, Idaho, United States
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 812
- Registration Number
- NCT00598806
- Locations
- 🇺🇸
PharmaTrials, Inc., Hillsborough, New Jersey, United States
🇵🇱Samodzielny Publiczny Zakład Opieki Zdrowotnej w Pabianicach, Pabianice, Poland
🇺🇸Advanced Urology Medical Center Clinical Trials, Anaheim, California, United States
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 802
- Registration Number
- NCT00461591
- Locations
- 🇺🇸
Urology of Virginia, PC, Virginia Beach, Virginia, United States
🇺🇸Delaware Valley Urology, LLC - Voorhees, Voorhees, New Jersey, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 53
- Registration Number
- NCT00141531
- Locations
- 🇳🇱
St Radboud University Hospital, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.